Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin

Summary

This study intends to conduct a single-arm, prospective and open clinical study, using carrellizumab combined with albumin-binding paclitaxel regimen for first-line treatment of squamous cell carcinoma of the skin, including 24 patients with squamous cell carcinoma of the skin, to further confirm the efficacy and safety of Carrellizumab combined with albumin-binding paclitaxel in the treatment of squamous cell carcinoma of the skin.

Timeline

Start

2023-06-08

Primary completion

2025-04-30

Completion

2025-04-30

Drugs

Indications